ReviewBlood reviews2012
Management of indolent lymphoma: where are we now and where are we going.
Review in Blood reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.Blood advances · 2021Trial
- Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.Haematologica · 2017Trial
- Trial
- PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.The New England journal of medicine · 2014Trial
- Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance.Cancer medicine · 2026Article
- Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes.Frontiers in medicine · 2022Article
- Whole-Body Magnetic Resonance Imaging: Current Role in Patients with Lymphoma.Diagnostics (Basel, Switzerland) · 2021Review
- Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.Targeted oncology · 2021Review
- Cardiovascular Diseases And Psychiatric Disorders During The Diagnostic Workup Of Suspected Hematological Malignancy.Clinical epidemiology · 2019Article
- A Case of Synchronous Bone Marrow Chronic Myelomonocytic Leukemia (CMML) and Nodal Marginal Zone Lymphoma (NMZL).The American journal of case reports · 2018Article
- Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.Journal of hematology & oncology · 2018Review
- Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now.European radiology · 2018Review
- Impact of obinutuzumab alone and in combination for follicular lymphoma.Blood and lymphatic cancer : targets and therapy · 2017Review
- Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.Blood advances · 2016Article
- Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.Leukemia & lymphoma · 2016Article
- Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential.OncoTargets and therapy · 2016Review
- Bortezomib for the treatment of non-Hodgkin's lymphoma.Expert opinion on pharmacotherapy · 2014Review
- Article
- Interleukin 12: still a promising candidate for tumor immunotherapy?Cancer immunology, immunotherapy : CII · 2014Review
- Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Indolent lymphoma comprises a unique and challenging subset of non-Hodgkin lymphoma (NHL). While definitions of indolence will vary, the most common indolent NHL subtypes include follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma. Patients with indolent NHL (iNHL) excluding those with rare localized presentations are often met with an incurable but highly treatable NHL. In the rituximab era, response rates are approaching 90% with rituximab plus chemotherapy and time to next treatment are beginning to be measured in years. As a result of a prolonged natural history, we are encountering a gridlock of novel regimens and agents that appropriately fill peer-reviewed journals. In this review, we tackle a spectrum of topics in the management of indolent lymphoma including the initial approach to the newly diagnosed patient, approaches to first cytotoxic chemotherapy, maintenance and consolidation techniques, as well as highlight promising treatments on the horizon in iNHL. Clinicians continue to face tough choices in the management of iNHL. Through well-thought out clinical trials and peer-reviewed vetting of data we will continue to determine how to best manage the clinical continuum that is iNHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.